Mark Spellman, Alpine Funds Co-Portfolio Manager, explains his views on finding yield in large-cap stocks over mid-caps and gives his picks. » Read More
CNBC Pro reached out to top Wall Street fund managers to find out where they are putting money to work ahead of a potential Fed rate increase.
Prescription drug prices are out of control, but there's a way to make your money back: The drugstore stocks are very healthy right now.
Louis Navellier, whose "Squawk Box" model portfolio is up 19% this year, shares his views on how to ride out the volatility in the market.
CVS customers in six states will get access to telehealth services starting in the fourth quarter.
Wells Fargo analyst Scott Wren explains why he's keeping his S&P price target at 2,150 to 2,250.
Subway took a hit losing its spokesman Jared to scandal. So, is it better to use a pitch dog like Snoopy?
Target posted earnings that beat analysts' expectations Wednesday, and chief financial officer John Mulligan sees more growth ahead.
Here's why Google's Alphabet reorg was a really smart move, says former Medtronic CEO Bill George.
Goldman Sachs told clients in a note on Friday the market will go sideways the rest of the year.
Jim Cramer speaks with Starbucks CEO Howard Schultz on working with competition to hire disenfranchised youth in the U.S.
With U.S. stocks choppy again Wednesday, investors sought safe picks in an increasingly uncertain market.
Goldman Sachs gave clients a list of 20 stocks they should avoid because of their high exposure to China.
With Costco, CVS and Walmart's photo sites going down due to cyberthreats, local retailers are picking up the business.
More than half of small businesses who accept point-of-sale card payments are not aware of a major change coming in October.
Discount retail chain CVS will no longer include Pfizer's Viagra in its list of drug insurance benefits, CNBC confirmed on Wednesday.
Some of the names on the move ahead of the open.
Greg Foran and Brian Cornell mark their one-year anniversaries at Walmart U.S. and Target next month.
One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.
Two Strategists favor U.S. stocks vs. global stocks
The US should build on what Starbucks is starting with its youth job-creation effort, says former Medtronic CEO Bill George.